Want to join the conversation?
Biopharma company $REGN and Sanofi said placebo-controlled Phase 3 studies, LIBERTY AD SOLO 1 and SOLO 2, testing dupilumab in adults with moderate-to-severe atopic dermatitis met their main endpoints. Treatment with dupilumab as monotherapy were found to improve overall disease severity, skin clearing, itching, quality of life and mental health.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.